Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of 4-Methoxysalicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Methoxysalicylic Acid SCHEMBL9277153 | 0.96 | NPC1 (0.70) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| 4-Methoxysalicylic Acid SCHEMBL25265671 | 0.83 | NPC1 (0.54) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| Zinc Ion SCHEMBL8653775 | 0.82 | NPC1 (0.53) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| Zinc Ion SCHEMBL26935 | 0.82 | NPC1 (0.53) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| SCHEMBL38652 | 0.82 | NPC1 (1.00) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| SCHEMBL1514997 | 0.82 | NPC1 (1.00) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| SCHEMBL29365072 | 0.82 | NPC1 (1.00) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| SCHEMBL192019 | 0.81 | NPC1 (0.55) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| SCHEMBL29918279 | 0.81 | NPC1 (0.55) | NPC1RAB9AHPGDCYP3A4MAPK1 | |
| SCHEMBL10453973 | 0.81 | NPC1 (0.96) | NPC1RAB9AHPGDCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 971 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079764-A | Method for synthesizing 4-methoxy potassium salicylate based on supermolecule assisted methylation | — | 2026-05-26 | — | — | CN | claimed |
| US-12551418-B2 | Cosmetic containing ultraviolet wavelength converting substance and medicinal agent | SHISEIDO COMPANY, LTD. (JP) | 2026-02-17 | — | — | US | claimed |
| CN-118512365-B | Composition with whitening effect and application of composition in cosmetics | 广东雅丽洁精细化工有限公司 | 2025-04-22 | — | — | CN | claimed |
| CN-119830923-A | Large model dialogue system for heart physiotherapy | 西湖心辰(杭州)科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119693999-A | Human body posture video evaluation method based on space-time diagram convolutional network | 长春大学 | 2025-03-25 | — | — | CN | claimed |
| US-20250053686-A1 | ANONYMITY ALGORITHM-BASED DATA SHARING PRIVACY PROTECTION METHOD | INSTITUTE OF MEDICAL INFORMATION, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-02-13 | — | — | US | claimed |
| CN-118568010-B | Cache data processing method, device, equipment, storage medium and program product | 中移动信息技术有限公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024219260-A1 | BEAUTY TREATMENT METHOD, METHOD FOR PROMOTING PERCUTANEOUS PENETRATION, AND BEAUTY TREATMENT KIT | 株式会社 資生堂 | 2024-10-24 | — | — | WO | claimed |
| CN-114599333-B | Method for using ultra-fine bubbles | 株式会社资生堂 | 2024-09-10 | — | — | CN | claimed |
| CN-118512365-A | Composition with whitening effect and application of composition in cosmetics | 广东雅丽洁精细化工有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-103717197-B | Water-in-oil-type skin-whitening cosmetic | SHISEIDO CO LTD | 2015-04-01 | — | — | CN | claimed |
| CN-104370737-A | Synthesis and preparation method of 4-methoxyl potassium salicylate | WANG YONGQUAN | 2015-02-25 | — | — | CN | claimed |
| US-8821905-B2 | Oil-in-water emulsified composition | SHISEIDO COMPANY, LTD. (JP) | 2014-09-02 | — | — | US | claimed |
| US-20140186281-A1 | WATER-IN-OIL-TYPE SKIN-WHITENING COSMETIC | SHISEIDO COMPANY, LTD. (JP) | 2014-07-03 | — | — | US | claimed |
| EP-2742929-A1 | WATER-IN-OIL-TYPE SKIN-WHITENING COSMETIC | Shiseido Company, Ltd. (JP) | 2014-06-18 | — | — | EP | claimed |
| CN-103822976-A | Method for measuring 4-potassium methoxysalicylate in cosmetics | LIAONING PROVINCE INST FOR FOOD AND DRUG CONTROL | 2014-05-28 | — | — | CN | claimed |
| US-20130189335-A1 | Oil-in-Water Emulsified Composition | SHISEIDO COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | claimed |
| US-8426435-B2 | Method for inhibiting melanin production and whitening skin with pyrimidlypyrazole compounds or pharmaceutically acceptable salts thereof | SHISEIDO COMPANY LTD. (JP) | 2013-04-23 | — | — | US | claimed |
| US-20130045173-A1 | Method For Inhibiting Melanin Production And Whitening Skin With Pyrimidlypyrazole Compounds Or Pharmaceutically Acceptable Salts Thereof | SHISEDIO COMPANY LTD. (JP) | 2013-02-21 | — | — | US | claimed |
| US-20130028950-A1 | Vesicle-Containing Composition | SHISEIDO COMPANY, LTD. (JP) | 2013-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186281-A1 | WATER-IN-OIL-TYPE SKIN-WHITENING COSMETIC | ALOX15, ALOX12, ALOX15B | NPC1 3161/4885RAB9A 4489/4885HPGD 1081/4885 |
| US-12551418-B2 | Cosmetic containing ultraviolet wavelength converting substance and medicinal agent | GLA, PGA5, AGER | NPC1 4040/4885RAB9A 4824/4885HPGD 132/4885 |
| US-20130028950-A1 | Vesicle-Containing Composition | VAPB, PHOSPHO1, CHMP4B | NPC1 1709/4885RAB9A 957/4885HPGD 4822/4885 |
| US-20130045173-A1 | Method For Inhibiting Melanin Production And Whitening Skin With Pyrimidlypyrazole Compounds Or Pharmaceutically Acceptable Salts Thereof | TYR, MC1R, TH | NPC1 3134/4885RAB9A 1668/4885HPGD 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.